Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight.
BACKGROUND
About 15% of patients who undergo adjustable gastric banding (AGB) have difficulty losing weight due to, among other factors, the development or maintenance of binge eating disorder. Topiramate is an anticonvulsive drug with proven good results in controlling binge eating episodes. The objective of this study was to analyze the effect of topiramate in patients with AGB.


METHODS
16 patients with binge eating and inadequate weight loss after AGB were analyzed prospectively for 3 months while receiving topiramate in doses varying from 12.5 to 50 mg per day.


RESULTS
There was a mean increase in excess weight loss from 20.4% to 34.1% without the need for band readjustment. 2 patients had intolerance to topiramate and were changed to fluoxetine 40 mg per day.


CONCLUSIONS
Topiramate may be a useful adjuvant for patients with AGB and binge eating disorder.
Zilberstein
Bruno
B
Gastromed-Instituto Zilberstein, Bariatric Surgery Department, Av 9 de juho 4440, CEP: 01406-100 São Paulo, Brazil. brunozilb@uol.com.br
Pajecki
Denis
D
Garcia de Brito
Alex Cleiton
AC
Gallafrio
Samuel Terra
ST
Eshkenazy
Rony
R
Andrade
Carla Granja
CG
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002032:Bulimia / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015391:Gastroplasty / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D000077236:Topiramate
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose